Contribution of a Three-Phase 99m Tc-HMDP Bone Scintigraphy Protocol Completed by SPECT-CT Scan in the Diagnosis and Management of Langerhans Cell Histiocytosis of Bones in an Adolescent. A Case Report and Review

Fabrice Fokoue*, Sanae El Mselmi, Nadia Abaouz, Nadia Ismaili Alaoui
Department of Nuclear Medicine, Oncology Hospital, Hassan II University Hospital Center, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, Fez, Morocco

Corresponding Author: Fabrice Fokoue, Department of Nuclear Medicine, Oncology Hospital, Hassan II University Hospital Center, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, Fez, Morocco.
Email: fabricefokoue2017@gmail.com; Phone: +212 0700561683

Received: July 24, 2020; Accepted: July 29, 2020; Published: August 09, 2020

Abstract

Langerhans Cell Histiocytosis (LCH) or Histiocytosis X is a rare disorder of the reticuloendothelial system due to the accumulation of Langerhans cells in the tissues, most often organized into granulomas. The bone is the most affected organ. It can be a single osteolytic lesion or a multi-systemic form with organ dysfunction. We report herein the case of a 15-year-old adolescent male with bone pain in the hip evolving for two months in whom the diagnosis of unifocal bone langerhansian Histiocytosis was confirmed by a triple phase bone scintigraphy supplemented by SPECT CT objectifying a single focus of the disease at the greater left trochanter of the femoral bone without any other pathological bone fixation clearly identifiable on the other parts of the skeleton. This clinical case allows us to clarify the key role of a triple phase bone scan supplemented by SPECT CT in the diagnosis and management of Langerhans Cell Histiocytosis of bone in our context.

Key Terms: Langerhansian Cell Histiocytosis of Bone; Bone Scintigraphy; SPECT CT


Introduction

Langerhansian Cell Histiocytosis (LCH) or X Histiocytosis is a rare disorder of the reticuloendothelial system due to an abnormal accumulation of Langerhans cells in the tissues, most often organized into a granuloma. The condition mainly occurs in children or young adults. The clinical presentation varies according to the affected tissues. It may be a single osteolytic lesion or a multi-systemic form with organ dysfunction. Bone remains the most affected tissue, followed by skin and pituitary gland. We report herein the case of a 15-year-old adolescent boy presenting with a bone pain in the left hip progressing for two months; in whom diagnostic imaging supplemented by a bone biopsy was in favor of a Langerhans Cell Histiocytosis of bone confirmed by the histological and immunohistochemical study. A bone scan was subsequently ordered confirming unifocal bone involvement. The aim of this work is to show the place of three-phase bone scintigraphy supplemented by SPECT CT in the initial management of Langerhans Cell Histiocytosis of bone.

Patient and Method

This is a 15-year-old boy, with no particular medical history admitted to the pediatric service for management of a bone pain in the left hip predominantly at night, with a partial response to the usual analgesics, evolving for 02 months after a notion of neglected trauma to the pelvis during a football game. The clinical examination highlighted a weight of 64 kg, a normal height for age with a normal dermatological and neurological examination, an absence of polyuropolydipsic syndrome. The rest of the clinical examination was unremarkable apart from the osteoarticular examination which revealed a slight localized pain in the left hip during palpation, with limitation of the flexion movement of the thigh on the torso and a slight lameness in the left hip. The initial biological assessment was normal with normal fasting blood glucose at the level of 5.2 mmol/L (3.89-6.2 mmol/L), SR, renal function and blood ionogram at a normal value. An MRI of the hip was performed after an initial pelvic X-ray showing a bone lesion in the left greater trochanter measuring 25 mm
x 23 mm x 21 mm associated with a hypo intense intra ossous edema in T1 with a T2 hyper signal which was intensely and evenly enhanced afterwards contrast injection. A bone biopsy was then performed on the bone lesion objectified by pelvic X-ray and MRI. Histological and immunohistochemical studies concluded to a Langerhans Cell Histiocytosis of bone. Standard x-rays of the pelvis, knees and skull taken as part of an initial extension workup returned with normal findings apart from the already known bone lesion in the left greater trochanter. The patient was subsequently referred to the nuclear medicine department for a bone scan to look for other sites of bone damage.

Results

We performed early static images centered on the pelvis between 0-10 min, then a full body scan examination and late static images supplemented by a SPECT CT focused on the pelvis 2 hours after an intravenous injection of 481 MBq (13 mCi) of Methylene Diphosphonate labeled with metastable Technetium 99 (MDP-99mTc). The early and late images were acquired with a Siemens dual head Gamma Camera, Symbia T6 2010 model. Bone scintigraphy carried out in 03 phases showed a moderate hyperemia of the left hip at the early stage and moderately intense bone hyperfixation of the left greater trochanter at the late stage. The complement by SPECT CT revealed the lacunar bone lesion previously described on the left greater trochanter both on standard radiographs (Fig. 1) and MRI (Fig. 2) without any other fixation or bone structure anomaly clearly identifiable on the entire skeleton thus making it possible to conclude to an unifocal presentation of the Langerhans Cell Histiocytosis of bone presented by the patient (Fig. 3, Fig. 4 and Fig. 5).

Figure 1. Frontal and Oblique X-Rays of the Left Hip Showing a Lacunar Image at the Level of the Left Greater Trochanter with a Geodic Aspect

Figure 2. MRI of the hip showing a bone lesion in the left greater trochanter with T2 discreet hyper signal, well limited T1 hyper signal and regular contours, surrounded by a border with T1 and T2 hypo intense without enhancement after injection of contrast. It measures 25mm x 23mm x 21mm and is accompanied by intraosseous edema in hypo intense T1, Hyper signal T2, which is intensely and evenly enhanced after injection of contrast.

Figure 3. Bone scintigraphy showing at the early stage (tissue) a slight hyperemia in the left hip and at the late stage an asymmetry of bone fixation opposite both two trochanters with a hyperfixation the left side

Figure 4. SPECT-CT examination focused on the left hip showing a lacunar osteolytic bone lesion of the left greater trochanter with a discreet bone hyperfixation

Figure 5. Whole body scan showing a single pathological bone hyperfixation opposite the left greater trochanter without any other pathological bone fixation clearly identifiable on the other parts of the skeleton.
Discussion

Langerhans Cell Histiocytosis is a rare disease which belongs to a group of conditions called Histiocytosis. In the general population the estimated annual incidence of LCH ranges from 0.5–5.4 cases per million of persons per year. LCH more frequently affects young adults, but it can also be seen in very young children. The incidence of LCH in children is determined as 2–9 per million of persons per year and is slightly predominant in males (M/F = 1.2–1.4). In our observation, the child was 15 years old adolescent male. Actually the pathogenesis of this condition is becoming more and more precise. Osteolytic bone involvement is the most common circumstance of discovery [1, 2].

LCH of bone can manifest as bone pain, broken bones or swelling. The clinical examination should always look for skin lesions because they have an important diagnostic value. The rapid spread of the disease to other organs is an actor of poor prognosis [2]. In our observation, the disease was revealed by bone pain localized in the left hip with no skin lesions and no involvement of other organs.

With regard to the pathogenesis of LCH, the cells involved are abnormal by their presence in many organs and tissues and by their oligodonal proliferation. These cells initially described by Paul Langerhans in 1868 belong to the reticulo-endothelial system. Initially, three forms of expression of the same disease were described:

- Letterer-Siwe's disease, an acute form of infants, characterized by multi-visceral involvement including hepatosplenomegaly and a very poor prognosis.
- Hand-Schüller-Christian disease, which combines exophthalmia, diabetes insipidus and cranial deficiencies. The coexistence of the three elements of this triad is however inconstant, found in only 10% of cases.
- Eosinophilic granuloma, mainly in older children, which is more frequently single than multiple and generally has a favorable outcome, affecting 60% of cases of LCH of bone in pediatric age.

In 1953, Lichtenstein highlighted histopathological similarities allowing these distinct clinical manifestations to be grouped under a single nosological entity, Histiocytosis X.

In 1973, Nizelof et al established that the pathophysiological link between these syndromes is the dysfunction of Langerhans cells. The disease is now called Langerhans Cell Histiocytosis [3]. Subsequently it was classified into 03 groups:

- Group 1 including Langerhans Cell Histiocytosis (all forms included);
- Group 2 comprising Non-Langerhans Cell Histiocytosis and Benign Histiocytosis (juvenile xanthogranuloma, Rosai-Dorfmann-Destombes disease, Erdheim-Chester disease, Lymphohistiocytosis, Hemophagocytic);
- Group 3 including Malignant Histiocytic diseases (malignant Histiocytosis and Histiocytic sarcoma).

In 2016, significant progress in cellular and molecular biology led to rapid changes in the diagnostic and therapeutic modalities of Histiocytosis and to a revision of their classification by Jean François Emile et al [3] in which Histiocytosis are listed in five main groups (Table 1).

Table 1. Classification of Histiocytosis according to J.F Emile et al. [3]

<table>
<thead>
<tr>
<th>Group L (Langerhans)</th>
<th>Langerhans Cell Histiocytosis (LCH)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Indeterminate Cell Histiocytosis</td>
</tr>
<tr>
<td></td>
<td>Erdheim-Chester disease (ECD)</td>
</tr>
<tr>
<td>Group C (Cutaneous)</td>
<td>Non-Langerhans Histiocytosis Cutaneous or mucocutaneous:</td>
</tr>
<tr>
<td></td>
<td>* Xanthogranuloma family</td>
</tr>
<tr>
<td></td>
<td>* “Juvenile non-xanthogranuloma” family</td>
</tr>
<tr>
<td></td>
<td>Cutaneous non-Langerhans Histiocytosis with component major systemic:</td>
</tr>
<tr>
<td></td>
<td>* Xanthogranuloma family: disseminated xanthoma</td>
</tr>
<tr>
<td></td>
<td>* “Non-xanthogranuloma” family: multicentric reticulohistiocytosis (MRH)</td>
</tr>
<tr>
<td>Group R (Rosai)</td>
<td>Familial Rosai-Dorfman-Destombes disease (FRDD): classic lymph node, extra lymph node, associated with tumors or autoimmune disease, unclassifiable</td>
</tr>
<tr>
<td></td>
<td>* Primary Malignant Histiocytosis: Histolytic sarcomas, Sarcomas with inter digital dendritic cells, Langerhans cell sarcomas.</td>
</tr>
<tr>
<td>Group M (Malignant)</td>
<td>* Secondary malignant histiocytosis: Associated with or following lymphoma or leukemia.</td>
</tr>
<tr>
<td>Group H (Hemophagoctysis)</td>
<td>Primary Hemophagocytic Lymphohistiocytosis and Secondary Hemophagocytic Lymphohistiocytosis</td>
</tr>
</tbody>
</table>

Table 2. Frequency and locations of mono-tissue forms of Langerhans Histiocytosis in children [3].

<table>
<thead>
<tr>
<th>Localisations</th>
<th>Frequencies (in percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone</td>
<td>70-80%</td>
</tr>
<tr>
<td>Skin</td>
<td>10-50%</td>
</tr>
<tr>
<td>ENT</td>
<td>&gt;15 %</td>
</tr>
<tr>
<td>Hypophysis</td>
<td>5-50%</td>
</tr>
<tr>
<td>Orbital</td>
<td>&lt;20%</td>
</tr>
<tr>
<td>Mouth</td>
<td>6%</td>
</tr>
<tr>
<td>Gastrointestinal tract</td>
<td>2-13%</td>
</tr>
<tr>
<td>Lung</td>
<td>5%</td>
</tr>
<tr>
<td>Liver</td>
<td>4%</td>
</tr>
<tr>
<td>Ganglia</td>
<td>&lt;10%</td>
</tr>
</tbody>
</table>

- **Group L** comprising Langerhans cell Histiocytosis and Erdheim-Chester disease which are now considered as inflammatory myeloid neoplasms with the discovery of mutations in the BRAFV600E and MAP2K genes in two thirds of patients;
• **Group C** including non-Langerhans skin diseases such as Multicentric Reticulohistiocytosis and Xanthoma Disseminatum;

• **Group R** including Rosai-Dorfman-Destombes disease;

• **Group M** (malignant histiocytosis) and group H (hemophagocytosis).

The osteoarticular manifestations of Histiocytosis are found in groups L, C and R.

The diagnostic criteria defined by the Histiocytic Society are as follows:

- **Presumed Diagnosis:** by light microscopy findings;

- **Probable Diagnosis:** by optical microscopy findings and 2 of the following markers: adenosine triphosphatase, D-mannosidase, peanut agglutinin104;

- **Definitive Diagnosis:** including optical microscopy findings and 1 of the following criteria:
  - Birbeck granules (electron microscopy, a long and expensive technique) or labeling of pathological cells with the CD1a antigen.

The S100 protein is present in LCH but is not specific since it is also demonstrated in Rosai Dorffmann Destombes disease. In our patient, histology and immunohistochemistry made it possible to make the definitive diagnosis of LCH, in particular by the demonstration within several tumor cells of an expression marked by the CD1a antigen, and an intense expression of the S100 protein. After establishing the definitive diagnosis, in addition to a meticulous ENT and stomatologic clinical examination and a biological workup including FBC, ionogram, CRP and liver workup, certain imaging examinations are generally requested. These are skeletal x-rays or even cross-sectional examinations; in particular CT or MRI centered according to clinical or biological call points [4, 5].

In our case study, a standard x-ray on the pelvis was initially carried out followed by a focused MRI both showing the bone lesion and thus allowed to perform a biopsy and curettage allowing the diagnosis to be made after a histological and immunohistochemical confirmation, and also to treat the patient.

With regard to the morphological imaging means generally used in first intention, standard radiographs are often oriented by the painful bone site and can show osteolysis with a geode image. CT can confirm the presence of osteolysis with a better analysis of the corticoperiosteal reaction and the extent of bone lesions, especially at the base of the skull. MRI can better identify the involvement of soft tissues adjacent to the bone [5, 6].

The role of bone scintigraphy has long been debated, because while it allows whole body examination with high sensitivity for detection, it has low specificity for precise anatomical analysis of bone lesions. Whole-body bone scintigraphy provides an initial mapping of bone lesions, but is less sensitive than radiography in the diagnosis of eosinophilic granuloma [6].

In LCH of bone, the whole body bone scintigraphy can show foci of hypofixation, but most often hyperfixation. Hyperfixation in this case corresponds to osteocondensing lesions and hypofixation to pure osteolytic lesions without edematous reaction. The edematous reaction corresponding to a hyperemia observed during vascular and / or tissue phase if a three-phase scintigraphy is performed. Normal fixation corresponds to small lesions or lesions where the tumor is still confined to the medullar canal.

The sensitivity of bone scintigraphy increases significantly for the detection of active and multiple lesions. Whole-body MRI has been shown to have better sensitivity than bone scans and whole skeletal x-rays, but all of these imaging modalities have comparable accuracy in the initial risk stratification in patients [7, 8].

The advent of SPECT CT hybrid imaging has made it possible to increasingly upgrade bone scintigraphy because it allows for a better initial extension assessment or a mapping of the disease by a complete functional imaging of the skeleton with anatomical location thus increasing the specificity and sensitivity of bone scintigraphy in detecting bone lesions, thus allowing a more adequate initial therapeutic decision. It may also have a role in the follow-up of treated patients who already have known bone lesions [7, 8].

A recent retrospective study on the additional value of PET CT scan has shown that an initial PET CT scan with 18FDG would better characterize the extent and specificity of certain locations compared to CT or MRI exams alone for all forms of Histiocytosis. In addition, 18FDG PET CT scan would be very useful for the evaluation of the metabolic response to immunomodulatory treatments when these are used [9, 10].

It has also been shown that 18FDG PET CT scan can provide information that bone scintigraphy might omit and is therefore superior to it. In addition to bone analysis it makes it possible to highlight, on the one hand, tissue and organ lesions, in particular ganglionic, splenic and hepatic damage, which may be omitted by other means of imaging and, on the other hand possibly to identify the possible sites bone biopsy, finally the PET CT scan could therefore be good exam for the follow-up of treated patients who already have known organ lesions [10-12].

In our case study, a three-phase bone scintigraphy centered on the pelvis was performed followed by a whole body bone scan, and SPECT CT imaging focused on the area of bone hyperfixation. This protocol allowed to establish a precise map of the bone damage by a panoramic analysis of the entire skeleton, and to confirm the unifocal nature of the bone damage by characterizing the unique bone lesion of the left greater trochanter objectified on standard radiographs and MRI centered on the painful area.

Regarding the therapeutic management of LCH of the bone, single or few bone lesions in number generally do not require any treatment, other than the biopsy or fine needle aspiration necessary to confirm the diagnosis and to reduce de pain.
Surgical treatment by curettage or osteosynthesis to reduce the risk of fracture may be prescribed. Multifocal forms of LCH can be an indication of chemotherapy alone or combined with corticosteroid therapy and / or external radiotherapy. The first line chemotherapy is Vincristine or Etoposide if indicated [1, 3, and 8].

External radiotherapy remains very delicate because of the risk of secondary cancer in the irradiation field. At moderate doses, between 10 and 15 grays, it can be useful in the event of a very extensive and / or extensive lesion.

Conclusion

Although 18-FDG PET CT seems to be the Gold standard in the initial extension workup and follow-up for Langerhans Cell Histiocytosis, our case study demonstrates the key role of HMMDP-99mTc bone scintigraphy supplemented by SPECT CT in the management of LCH of the bone, thus making it possible to establish an initial lesion mapping of the bone sites affected, by an accurate analysis of the entire skeleton. It thus allows easier subsequent monitoring with better diagnostic value and better value for money compared to other imaging methods with acceptable overall dosimetry.

Authors' Contributions

All the authors contributed to the realization of this work.

Declaration of Patient Consent

The authors certify that they have obtained the appropriate patient consent.

Financial Support and Sponsorship

Nil.

Conflicts of Interest

The authors declare no conflict of interest.

References
